Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.

被引：0

作者：

Suzuki, Maya ^{[1
]}

Cheung, Irene Y. ^{[1
]}

Cheung, Nai-Kong V. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.10570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10570

引用

页数：2

共 50 条

[31] Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
Mueller, Ina
Ehlert, Karoline
Endres, Stefanie
Pill, Lena
Siebert, Nikolai
Kietz, Silke
Brock, Penelope
Garaventa, Alberto
Valteau-Couanet, Dominique
Janzek, Evelyne
Hosten, Norbert
Zinke, Andreas
Barthlen, Winfried
Varol, Emine
Loibner, Hans
Ladenstein, Ruth
Lode, Holger N.
MABS, 2018, 10 (01) : 55 - 61
[32] Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab
Siebert, Nikolai
Seidel, Diana
Eger, Christin
Brackrock, Diana
Reker, Daniel
Schmidt, Manuela
Lode, Holger N.
JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 398 : 51 - 59
[33] Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.
Kayser, Simone
Icheva, Vanya
Stevanovic, Stefan
Siebert, Nikolai
Feucht, Judith
Lode, Holger N.
Handgretinger, Rupert
Feuchtinger, Tobias
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
Desai, Ami Vijay
Fox, Elizabeth
DiSipio, Theresa C.
Smith, L. Mary
Lim, Allison
Maris, John M.
Balis, Frank M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[35] Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Escalante Romero, L.
Queiroz Costa Neto, I.
Antunes, V. L. J.
Matos Correia Rodrigues, M.
Polo Mercado, J. R.
Monteiro Caran, E.
ANNALS OF ONCOLOGY, 2024, 35 : S694 - S695
[36] ANTI-GD2 IMMUNOTHERAPY WITH G-CSF AND INTERLEUKIN-2 FOR HIGH-RISK NEUROBLASTOMA
Honda, Mamoru
Arakawa, Yuki
Kaneko, Ryota
Kubota, Hirohito
Mitani, Yuichi
Mori, Makiko
Fukuoka, Kohei
Oshima, Koichi
Isshiki, Kyohei
Koh, Katsuyoshi
PEDIATRIC BLOOD & CANCER, 2022, 69
[37] Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients
Lode, Holger
Jensen, Christian
Siebert, Nikolai
Kietz, Silke
Ehlert, Karoline
Mueller, Ina
Ladenstein, Ruth
Janzek, Evelyne
Loibner, Hans
CANCER RESEARCH, 2014, 74 (19)
[38] Comparison of Pain Outcomes Between Two Anti-GD2 Antibodies in Patients With Neuroblastoma
Anghelescu, Doralina L.
Goldberg, Jacob L.
Faughnan, Lane G.
Wu, Jianrong
Mao, Shenghua
Furman, Wayne L.
Santana, Victor M.
Navid, Fariba
PEDIATRIC BLOOD & CANCER, 2015, 62 (02) : 224 - 228
[39] Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
Zobel, Michael John
Zamora, Abigail K.
Wu, Hong-wei
Sun, Jianping
Lascano, Danny
Malvar, Jemily
Wang, Larry
Sheard, Michael A.
Seeger, Robert C.
Kim, Eugene S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[40] Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin
Kushner, Brian H.
Ostrovnaya, Irina
Cheung, Irene Y.
Kuk, Deborah
Modak, Shakeel
Kramer, Kim
Roberts, Stephen S.
Basu, Ellen M.
Yataghene, Karima
Cheung, Nai-Kong V.
ONCOTARGET, 2016, 7 (04) : 4155 - 4166

← 1 2 3 4 5 →